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ABSTRACT
CONTEXT AND OBJECTIVE: The main causes of hepatic steatosis (HS) are alcoholic liver disease and nonalcoholic fatty liver disease (nAFLD). Although 
liver biopsy is the gold standard for nAFLD diagnosis, the finding of abnormal aminotransferases in abstinent individuals, without known liver disease, 
suggests the diagnosis of nAFLD in 80-90% of the cases. identification of clinical factors associated with HS on abdominal ultrasound may enable 
diagnoses of fatty liver non-invasively and cost-effectively. The aim here was to identify clinical variables associated with HS in individuals with elevated 
alanine aminotransferase (ALT) levels. 
DESIGN AND SETTING: Cross-sectional study in a single tertiary care center.
METHODS: individuals with elevated ALT, serologically negative for hepatitis B and C, were evaluated by reviewing medical files. Patients who did not 
undergo abdominal ultrasonography were excluded. 
RESULTS: Among 94 individuals included, 40% presented HS on ultrasonography. Compared with individuals without HS, those with fatty liver 
were older (P = 0.043), with higher body mass index (BMi) (P = 0.003), diabetes prevalence (P = 0.024), fasting glucose levels (P = 0.001) and 
triglycerides (P = 0.003). Multivariate analysis showed that  BMi (odds ratio, OR = 1.186; 95% confidence interval, Ci: 1.049-1.341; P = 0.006) and 
diabetes mellitus (OR = 12.721; 95% Ci: 1.380-117.247; P = 0.025) were independently associated with HS.
CONCLUSIONS: Simple clinical findings such as history of diabetes and high  BMi may predict the presence of HS on ultrasonography in individuals 
with elevated ALT and negative serological tests for hepatitis. 
RESUMO
CONTEXTO E OBJETIVO: Doença hepática alcoólica e doença hepática esteatótica não alcoólica (DHenA) são as principais causas de esteatose 
hepática (eH). Apesar de a biópsia hepática ser o método de escolha para diagnóstico DHenA, o achado de aminotransferases elevadas em 
indivíduos abstêmios, sem doença hepática conhecida, sugere o diagnóstico de DHenA em 80-90% dos casos. A identificação de variáveis clínicas 
associadas à eH na ultrassonografia abdominal pode permitir o diagnóstico de DHenA de forma não invasiva e custo-efetiva. O objetivo foi identificar 
variáveis clínicas associadas à eH em indivíduos com níveis elevados de alanina aminotransferase (ALT). 
TIPO DE ESTUDO E LOCAL: estudo transversal em um único centro de atendimento terciário.
MÉTODOS: indivíduos com ALT elevada e sorologias negativas para os vírus de hepatite B e C foram avaliados por meio de revisão de prontuários. 
Os pacientes não submetidos à ultrassonografia foram excluídos. 
RESULTADOS: Foram incluídos 94 indivíduos, 40% deles com eH à ultrassonografia. Quando comparados aos indivíduos sem eH, aqueles com eH 
apresentaram maior prevalência de diabetes (P = 0,024), maiores idade (P = 0,043) e índice de massa corpórea (iMC) (P = 0,003), glicemia de 
jejum mais elevada (P = 0,001) e triglicerídeos mais elevados (P = 0,003). A análise multivariada evidenciou que o iMC (odds ratio, OR = 1,186, 
95% intervalo de confiança, iC 1,049-1,341, P = 0,006) e o diabetes mellitus (OR = 12,721, 95% iC 1,380-117,247, P = 0,025) foram associadas 
independentemente à eH. 
CONCLUSÕES: Achados clínicos simples como história de diabetes e o  iMC elevado podem predizer a presença de eH à ultrassonografia de 
indivíduos com ALT elevada e sorologias negativas para hepatite. 
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INTRODUCTION
Hepatic steatosis is a generic term that refers to the accumulation 
of triglycerides in the cytoplasm of hepatocytes. Fatty liver is usually 
diagnosed in individuals without clinical evidence of liver disease, after 
fortuitous identification of elevated serum aminotransferase levels. It 
is an important pathological condition because of its high prevalence, 
affecting about 25 to 35% of the United States adult population.1 
The main conditions associated with the presence of fatty liver are al-
coholic liver disease and nonalcoholic fatty liver disease (NAFLD).2 
Fatty liver can also occur due to various other etiological factors, in-
cluding the use of medications (such as tamoxifen and methotrexate) 
and toxins (such as carbon tetrachloride and arsenic) and the presence 
of chronic viral hepatitis B and C (most commonly in hepatitis C in-
fection) and other metabolic diseases (such as hemochromatosis and 
Wilson’s disease).3
The evolution of liver disease is variable, according to the cause 
of steatosis. In alcoholic liver disease, the stages are similar to those of 
NAFLD and progress from steatosis to steatohepatitis with varying de-
grees of fibrosis, which can lead to cirrhosis. In viral hepatitis, liver fi-
brosis progression to cirrhosis is due to the presence of chronic active 
hepatitis.4 Even if the evolution of NAFLD depends on the causative 
factor, the early stages may be reversible if early intervention is taken to 
remove the offending factor. Individuals with advanced fibrosis exhibit 
an increased risk of developing hepatocellular carcinoma, although this 
risk is less common in NAFLD than is seen in cirrhosis due to alcohol 
or the hepatitis C virus.5
NAFLD is the most common cause of hepatic steatosis, along with 
elevated aminotransferase levels, and is present in 2.8 to 5.5 percent of 
the population.2 Suspected NAFLD is among the leading causes of out-
patient consultations with gastroenterologists and hepatologists.2,6 Al-
though some patients are found to present painful hepatomegaly, the 
vast majority are asymptomatic, and liver disease is identified inciden-
tally from routine laboratory tests or imaging. Its initial assessment con-
sists of ruling out other causes of liver disease and identifying clinical 
comorbidities, particularly metabolic disorders.7
The risk factors for NAFLD include obesity, diabetes mellitus, insu-
lin resistance, dyslipidemia and systemic hypertension.6,8,9 However, not 
all patients with metabolic syndrome develop hepatic steatosis. Labora-
tory tests frequently show changes in liver damage markers, particularly 
alanine aminotransferase (ALT), aspartate aminotransferase (AST) and 
gamma-glutamyltransferase (GGT).6,8-9 In NAFLD, the ALT level is not 
correlated with the degree of histological activity and may be normal, 
even in the presence of advanced disease.9
Although liver biopsy is considered to be the gold standard meth-
od for diagnosing and staging NAFLD, the finding of abnormal liv-
er enzyme levels in individuals who do not abuse alcohol and do not 
have any known liver disease or risk factors suggests the diagnosis of 
NAFLD in 80-90% of the cases.8 Identification of clinical and labora-
tory features associated with steatosis on abdominal ultrasound may 
make it possible to diagnose fatty liver in a non-invasive and cost-ef-
fective manner.
OBJECTIVE
The objective of this study was to identify the clinical and labo-
ratory variables associated with steatosis on ultrasound examinations, 
among blood donors with elevated ALT and negative serological tests 
for hepatitis B and C viruses.
MATERIALS AND METHODS
Patients
This cross sectional study was carried out in a single tertiary care 
center (Hepatitis Section, Hospital São Paulo) and included donors 
who had been referred by the blood bank because they presented el-
evated ALT levels but were serologically negative for hepatitis B and 
C (hepatitis B surface antigen [HBsAg], antibody to hepatitis B core 
antigen [anti-HBc] and anti-hepatitis C virus antibody [anti-HCV]), 
between September 1997 and August 2006. Patients who did not un-
dergo abdominal ultrasonography were excluded. 
The study protocol conformed to the ethical guidelines of the 1975 
Helsinki Declaration and was approved by our institutional review 
board.
Methods
Demographic, laboratory, ultrasound and other clinical variables 
were reviewed and extracted from standardized medical records. Only 
clinical data, laboratory tests and ultrasonography obtained within three 
months from the first medical consultation were used for this study. The 
patients included were analyzed for the following clinical and epidemi-
ological characteristics: gender, age, body mass index (BMI), history of 
diabetes mellitus, history of dyslipidemia, alcohol abuse, occupational 
activity (healthcare field or other activity), risky sexual behavior (defined 
by identifying promiscuity [three or more partners within six months], 
previous sexually transmitted disease or homosexuality), and exposure 
to parenteral risk (characterized by parenteral use of drugs with sharing 
of injection equipment [intravenous drugs or illegal energy substances] 
or transfusion of blood components). History of diabetes mellitus was 
defined by previously diagnosed fasting glucose ≥ 126 mg/dl or glu-
cose ≥ 200 mg/dl at any time, associated with symptoms or detected in 
an oral glucose tolerance test. History of dyslipidemia was defined as a 
prior diagnosis of hypertriglyceridemia (triglycerides ≥ 150 mg/dl) and/
or hypercholesterolemia (total cholesterol ≥ 200 mg/dl) and/or HDL 
< 50 mg/dl in women and < 40 mg/dl in men. Alcohol abuse was de-
fined as reporting of alcohol consumption exceeding 20 g per day for 
women and 30 g per day for men one year prior to enrollment. Ultra-
sound data, regarding the presence or absence of hepatic steatosis, was 
obtained from the medical records. 
With regard to the biochemical variables analyzed, ALT, AST, alka-
line phosphatase (ALP) and GGT were expressed in the form of an in-
dex calculated as the ratio between the values obtained and the upper 
limit of normality (ULN). Thus, a test result was considered high when 
the resulting value was equal to or more than one ULN. The other pa-
rameters were expressed as absolute values.
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Statistical analysis
Continuous variables were compared using Student’s t test, or the 
Mann-Whitney U test when appropriate. Categorical variables were 
compared using Pearson’s c2 test or Fisher’s exact test. P-values of less 
than 0.05 were considered statistically significant. Bivariate analysis 
and regression analysis were used to identify variables associated with 
the presence of liver steatosis on ultrasound. All tests were two-tailed 
and were performed using the Statistical Package for the Social Sciences 
(SPSS) software, version 15.0 (SPSS, Chicago, Illinois, USA).
RESULTS 
Patient characteristics
During the study period, which covered nine years, 2,315 blood do-
nors were referred from blood banks to the Hepatitis Division of Univer-
sidade Federal de São Paulo (Unifesp), Brazil, with abnormal liver test re-
sults. Among the subjects studied, 71 had insufficient data in the records. 
With regard to the reason for referral, 320 donors (14.3%) were attended 
because of high levels of ALT; 1,273 (56.7%) because of HBsAG and/
or anti-HBc positive or inconclusive tests; and 651 (29.0%) because of 
reactive or inconclusive anti-HCV results. Among the 320 subjects with 
elevated ALT levels and negative serological test results for viral hepati-
tis considered for inclusion in the study, 226 were excluded because they 
had not undergone abdominal ultrasound. The patient distribution is 
shown in Figure 1. 
The mean age was 37.0 ± 9.5 years, the mean BMI was 29.6 ± 4.6 
kg/m2 and male predominance was observed (88%). Ten percent of the 
patients had previously been diagnosed with diabetes, 54% had dyslip-
idemia and 26% had a history of alcohol abuse. The characteristics of 
the 94 individuals included in the study are shown in Table 1. Given 
the high number of patients excluded, a comparative analysis was per-
formed between them and the individuals included in the study (those 
who underwent ultrasonography) (Table 1). Overall, demographic and 
clinical characteristics were similar between the included and excluded 
individuals. The patients included were older than the patients excluded 
(37.0 ± 9.5 versus 34.1 ± 8.9; P = 0.010). 
Factors associated with liver steatosis 
Comparison of individuals with hepatic steatosis and those who 
did not have steatosis on ultrasound showed that the individuals with 
steatosis were older (39.3 ± 10.0 versus 35.3 ± 8.8 years; P = 0.043) 
and had higher BMI (31.6 ± 5.3 versus 28.4 ± 3.6 kg/m2; P = 0.003) 
and higher prevalence of diabetes (20.6% versus 3.6%; P = 0.024). 
The distribution of the clinical and epidemiological characteristics of 
the 94 patients according to the presence of steatosis on ultrasonog-
raphy is shown in Table 2. Patients with steatosis on ultrasonography 
showed higher mean fasting glucose levels (118.4 ± 47.7 versus 98.7 
± 35.8 mg/dl; P = 0.001) and higher mean triglyceride levels (203.9 
± 104.9 versus 147.6 ± 90.9 mg/dl; P = 0.003). Biochemical variables 
according to the presence of steatosis at ultrasonography are shown 
in Table 3.
Multivariate analysis showed that BMI (odds ratio, OR = 1.186; 
95% confidence interval, CI: 1.049 to 1.341; P = 0.006) and history of 
diabetes mellitus (OR = 12.721; 95% CI: 1.380 to 117.247; P = 0.025) 
were independently associated with the presence of steatosis on ultra-
sonography.
DISCUSSION
Investigation of factors associated with steatosis has been highlight-
ed in the medical literature over recent years. This is because of its high 
prevalence: it is the most common cause of chronic liver disease among 
adults and children in the United States.10
The prevalence of fatty liver disease depends on the population 
studied and the method used for diagnosis. In the general population, 
the prevalence of fatty liver disease is 16 to 29% on ultrasonography,11 
31 to 34% on  magnetic resonance imaging (MRI)1,12 and 15 to 39% 
on liver biopsy.13
2,315 blood donors 
1,273 with HBsAg 
and/or anti-HBc (+)
320 with elevated ALT 651 with anti-HCV (+) 
71 with insufcient data 
94 patients included 
226 without ultrasound 
Absence of steatosis 
n = 56  
(60%) 
Presence of steatosis 
n = 38 
(40%) 
Exclusion  
Figure 1. Distribution of potential candidates for participation in the study, candidates excluded and reasons for exclusion.
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Liver biopsy remains the gold standard method for diagnosing and 
staging fatty liver, since it enables fat quantification and identification 
of steatohepatitis and different degrees of fibrosis.14 However, it is an in-
vasive procedure, and the morbidity rates are certainly not negligible. 
Among the potentially serious complications, internal bleeding, bladder 
perforation, peritonitis, hematoma and infection can be mentioned. In 
fact, about 3% of the patients require hospitalization after undergoing 
liver biopsy.15 Pain following the procedure and high cost are common 
causes of dissatisfaction. Furthermore, studies have shown that histolog-
ical evaluations may be complicated by the possibility of sampling error 
and by considerable interobserver and intraobserver variability. Liver bi-
opsies allow histological analysis on 1/50,000 of the liver.16 The distri-
bution of lipid deposits in fatty liver cases may be heterogeneous, and 
therefore, a single liver biopsy may not adequately represent the disease 
throughout the liver.17 Hence, special attention has been given to non-
invasive methods for identifying and quantifying hepatic steatosis. The 
conventional methods include abdominal ultrasonography, computed 
tomography (CT) and MRI .4
Ultrasonography is the method of choice for the initial assessment 
of hepatic steatosis, since it presents a number of advantages over oth-
Table 1. Comparative analysis on 94 patients included in the study and 226 individuals excluded, regarding their clinical, epidemiological and biochemical 
characteristics
BMi = body mass index; AST = aspartate aminotransferase; ALT = alanine aminotransferase; DB = direct bilirubin; ALP = alkaline phosphatase; GGT = gamma glutamyltransferase; *Student´s t test, Mann-Whitney test, χ2 test or 
Fisher’s exact test, when appropriate for group comparisons; †Mean ± standard deviation and median.
Characteristics
Excluded from the study
n = 226
Included in the study
n = 94
P*
Male, n (%) 206 (91.2) 83 (88.3) 0.432
Age (years)† 34.1 ± 8.9 (33.0) 37.0 ± 9.5 (35.0) 0.010
BMi (kg/m²)† 28.9 ± 4.4 (28.6) 29.6 ± 4.6 (28.3) 0.206
Diabetes, n (%) 11 (5.4) 9 (10.1) 0.141
Dyslipidemia, n (%) 92 (50.8) 48 (53.9) 0.631
Alcohol abuse, n (%) 84 (37.7) 24 (26.4) 0.056
Health professionals, n (%) 5 (2.2) 1 (1.1) 0.675
Risky sexual behavior, n (%) 53 (23.8) 30 (33.0) 0.093
exposure to parental risk, n (%) 6 (2.7) 3 (3.3) 0.724
AST (xLSn)† 1.4 ± 2.7 (1.0) 1.1 ± 0.8 (0.9) 0.150
ALT (xLSn)† 1.9 ± 1.6 (1.6) 1.6 ± 0.6 (1.5) 0.237
DB (mg/dL)† 0.3 ± 0.3 (0.3) 0.3 ± 0.1 (0.3) 0.372
ALP (xLSn)† 0.7 ± 0.3 (0.7) 0.7 ± 0.2 (0.7) 0.785
GGT (xLSn)† 2.1 ± 1.8 (1.4) 2.1 ± 1.7 (1.5) 0.483
Prothrombin activity (%)† 92.8 ± 9.5 (97.5) 92.6 ± 9.7 (100.0) 0.962
Albumin (g/dl)† 4.4 ± 0.4 (4.4) 4.5 ± 0.5 (4.5) 0.415
Platelets (/mm³)† 231,200 ± 54,073 (222,000) 230,340 ± 50,408 (230,000) 0.920
Fasting glucose (g/dl) 99.4 ± 34.7 (91.0) 106.9 ± 42.0 (96.5) 0.082
Total cholesterol (mg/dl) 215.2 ± 53.4 (210.0) 202.0 ± 40.2 (198.5) 0.053
HDL cholesterol (mg/dl) 43.9 ± 12.2 (43.0) 44.1 ± 10.8 (42.5) 0.430
LDL cholesterol (mg/dl) 130.9 ± 41.7 (136.0) 123.1 ± 34.9 (124.0) 0.174
Triglycerides 221.9 ± 254.5 (160.0) 170.8 ± 100.27 (148.0) 0.367
ALT = alanine aminotransferase; BMi = body mass index; *Mean ± standard deviation and median; ‡Student’s t test, Mann-Whitney test, χ2 test or Fisher’s exact test, as appropriate for group comparisons.
Table 2. Distribution of clinical and epidemiological characteristics among 94 blood donors with elevated ALT, according to the presence of hepatic 
steatosis on ultrasonography
Characteristics
Ultrasonography
P*Absence of steatosis
n = 56
(60%)
Presence of steatosis
n = 38
(40%)
Male, n (%) 51 (91.1) 32 (84.2) 0.342
Age (years)† 35.3 ± 8.8 (35.0) 39.3 ± 10.0 (37.5) 0.043
BMi (kg/m²)† 28.4 ± 3.6 (27.7) 31.6 ± 5.3 (30.7) 0.003
Diabetes, n (%) 3 (3.6) 7 (20.6) 0.024
Dyslipidemia, n (%) 27 (50.0) 21 (60.0) 0.355
Alcohol abuse, n (%) 17 (32.1) 7 (18.4) 0.145
Health professionals, n (%) 0 (0.0) 1 (2.6) 0.409
Risky sexual behavior, n (%) 18 (34.0) 12 (31.6) 0.811
exposure to parental risk, n (%) 1 (1.9) 2 (5.3) 0.567
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Biochemical variables
Ultrasonography
P*Absence of steatosis
n = 56
Presence of steatosis
n = 38
AST (xLSn)† 1.0 ± 0.7 (0.9) 1.6 ± 0.9 (0.9) 0.500
ALT (xLSn)† 1.6 ± 0.6 (1.5) 1.6 ± 0.6 (1.5) 0.695
DB (mg/dl)† 0.3 ± 0.1 (0.3) 0.3 ± 0.1 (0.3) 0.880
ALP (xLSn)† 0.7 ± 0.2 (0.6) 0.7 ± 0.3 (0.7) 0.103
GGT (xLSn)† 2.3 ± 1.8 (1.8) 1.9 ± 1.6 (1.3) 0.369
Prothrombin activity (%)† 94.0 ± 8.7 (100.0) 90.8 ± 11.0 (97.4) 0.270
Albumin (g/dl)† 4.5 ± 0.5 (4.5) 4.4 ± 0.6 (4.5) 0.908
Platelets (/mm³)† 221,450 ± 50,890 (221,500) 244,420 ± 47,283 (251,000) 0.080
Fasting glucose (g/dl) 98.7 ± 35.8 (91.5) 118.4 ± 47.7 (105.0) 0.001
Total cholesterol (mg/dl) 200.7 ± 43.3 (196.0) 203.9 ± 35.7 (204.0) 0.723
HDL cholesterol (mg/dl) 44.8 ± 12.0 (42.5) 43.1 ± 8.8 (42.5) 0.785
LDL cholesterol (mg/dl) 124.2 ± 38.2 (124.5) 121.5 ± 29.9 (118.0) 0.749
Triglycerides (mg/dl) 147.6 ± 90.9 (113.0) 203.9 ± 104.9 (174.0) 0.003
Table 3. Distribution of biochemical variables among 94 blood donors with elevated ALT, according to the presence of hepatic steatosis on ultrasonography
xLSn = times the upper limit of normality; AST = aspartate aminotransferase; ALT = alanine aminotransferase; DB = direct bilirubin; ALP = alkaline phosphatase; GGT = gamma glutamyltransferase; *Student’s t test or Mann-Whitney 
test, as appropriate for group comparisons. †Mean ± standard deviation and median.
er imaging methods: low cost, safety, non-use of intravenous contrast, 
wide availability and widespread acceptance by patients.18 In the pres-
ence of hepatic steatosis, hyperechogenicity is observed on ultrasound 
examination in the liver parenchyma, associated with changes in echo 
texture, vascular blurring and deep attenuation. This corresponds to ste-
atotic infiltration greater than 30% in both liver lobes, with sensitivity 
of 60 to 95% and specificity of 77 to 100%.18
NAFLD prevalence increases with age, type 2 diabetes mellitus, 
obesity and hypertriglyceridemia.6,19 The association of NAFLD with 
gender is controversial: earlier studies indicated that NAFLD is more 
frequent among women, possibly because these studies included indi-
viduals referred to gastroenterologists. More recently, in population-
based studies, there has not been any such relationship.19 Visceral obesi-
ty, defined by a high waist-hip ratio, is also considered to be a risk factor 
for NAFLD. The presence of hyperinsulinemia or insulin resistance and 
associations with some components of metabolic syndrome suggest that 
NAFLD may be the hepatic manifestation of metabolic syndrome.20 
Most studies have evaluated the risk factors for NAFLD using liver bi-
opsy, but few studies have evaluated the risk factors for the presence of 
fatty liver on ultrasonography.
This study demonstrated that BMI and history of diabetes mellitus 
were independently associated with steatosis on abdominal ultrasound 
examination. Similar results were found by Ryan et al.,21 who assessed 
the presence of fatty liver on ultrasonography among HIV-positive in-
dividuals. Hepatic steatosis is present in two thirds of the obese popu-
lation, regardless of the presence of diabetes,22 and in more than 90% 
of morbidly obese individuals.23 Not only is obesity a predisposing fac-
tor for the emergence of type 2 diabetes and metabolic syndrome itself, 
but also its association with diabetes may represent an additional risk 
for the development of NAFLD. In a study evaluating obese patients 
with diabetes, 100% had steatosis, 50% had steatohepatitis and 19% 
had cirrhosis.23
This study has some limitations. Firstly, the retrospective data col-
lection and the large number of excluded patients may have led to selec-
tion bias. However, the data were collected from standardized medical 
files by a single researcher and the characteristics of the individuals ex-
cluded from the study were generally similar to those of the individuals 
included. Secondly, the strict inclusion of subjects with elevated ALT 
could represent a limitation, because it is known that individuals with 
normal ALT may have hepatic steatosis. However, ALT is used as part of 
the laboratory tests requested for checkups, and because abnormal ALT 
levels suggest that liver disease is present, it is a frequent cause of refer-
ral to specialists. For this reason, the patients included in this study rep-
resent a valid population for evaluation. Finally, the use of ultrasound 
for diagnosing fatty liver is a less sensitive and specific method than liver 
biopsy. Ultrasound is also an examiner-dependent method, and it was 
not performed by a single examiner. However, as mentioned earlier, ul-
trasonography has an excellent cost-effectiveness ratio and it is widely 
available and easy to perform. For these reasons, it is the preferred test 
for use in the initial evaluation on patients with ALT elevation.24,25 Fur-
thermore, the fact that the ultrasound data was obtained from the med-
ical records may represent an advantage, since this reflects day-to-day 
clinical practice.
CONCLUSIONS
In conclusion, hepatic steatosis is frequently found in patients re-
ferred because of elevated ALT and negative serological tests for viral 
hepatitis. Simple clinical findings such as a history of diabetes mellitus 
and high BMI may predict the presence of fatty liver on ultrasonogra-
phy among these patients.
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